

S Stevens Negus

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/1663340/publications.pdf>

Version: 2024-02-01

208
papers

7,737
citations

44069

48
h-index

76900

74
g-index

215
all docs

215
docs citations

215
times ranked

4086
citing authors

#	ARTICLE	IF	CITATIONS
1	Contextual extinction of drug-associated discriminative stimuli fails to attenuate drug-food choice in rhesus monkeys. <i>Journal of the Experimental Analysis of Behavior</i> , 2022, 117, 505-517.	1.1	1
2	Lack of effect of the nociceptin opioid peptide agonist Ro 64-6198 on pain-depressed behavior and heroin choice in rats. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109255.	3.2	3
3	Acute pain-related depression of operant responding maintained by social interaction or food in male and female rats. <i>Psychopharmacology</i> , 2022, 239, 561-572.	3.1	15
4	Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimers. <i>Bioorganic Chemistry</i> , 2022, 120, 105641.	4.1	5
5	Opioid-like adverse effects of tianeptine in male rats and mice. <i>Psychopharmacology</i> , 2022, 239, 2187-2199.	3.1	9
6	Effects of the 5-HT _{2A} receptor antagonist volinanserine on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents. <i>Psychopharmacology</i> , 2022, 239, 1665-1677.	3.1	16
7	Editorial: Preclinical Animal Models and Measures of Pain: Improving Predictive Validity for Analgesic Drug Development. <i>Frontiers in Pain Research</i> , 2022, 3, 867786.	2.0	1
8	Role of Efficacy as a Determinant of Locomotor Activation by Mu Opioid Receptor Ligands in Female and Male Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 382, 44-53.	2.5	10
9	A synthetic opioid vaccine attenuates fentanyl-vs-food choice in male and female rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108348.	3.2	18
10	Temporal parameters of enhanced opioid reward after initial opioid exposure in rats. <i>Psychopharmacology</i> , 2021, 238, 725-734.	3.1	3
11	Behavioral Battery for Testing Candidate Analgesics in Mice. II. Effects of Endocannabinoid Catabolic Enzyme Inhibitors and Δ^9 -Tetrahydrocannabinol. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 242-253.	2.5	6
12	Behavioral Battery for Testing Candidate Analgesics in Mice. I. Validation with Positive and Negative Controls. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 232-241.	2.5	10
13	Factors mediating pain-related risk for opioid use disorder. <i>Neuropharmacology</i> , 2021, 186, 108476.	4.1	14
14	Lack of effect of different pain-related manipulations on opioid self-administration, reinstatement of opioid seeking, and opioid choice in rats. <i>Psychopharmacology</i> , 2021, 238, 1885-1897.	3.1	14
15	Some effects of putative G-protein biased mu-opioid receptor agonists in male rhesus monkeys. <i>Behavioural Pharmacology</i> , 2021, 32, 453-458.	1.7	4
16	Confronting the challenge of failed translation in medications development for substance use disorders. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 210, 173264.	2.9	12
17	A strategy to prioritize emerging drugs of abuse for analysis: Abuse liability testing using intracranial self-stimulation (ICSS) in rats and validation with Δ^9 -pyrrolidinohexanophenone (Δ^9 -PHP). <i>Emerging Trends in Drugs, Addictions, and Health</i> , 2021, 1, 100004.	1.1	4
18	Medications Development for Treatment of Opioid Use Disorder. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a039263.	6.2	13

#	ARTICLE	IF	CITATIONS
19	Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 374-384.	2.5	8
20	Animal Models to Evaluate Expression, Mechanisms, and Treatment of Pain. , 2021, , .		0
21	Morphine Exacerbates Experimental Colitis-Induced Depression of Nesting in Mice. <i>Frontiers in Pain Research</i> , 2021, 2, 738499.	2.0	5
22	Attenuated dopamine receptor signaling in nucleus accumbens core in a rat model of chemically-induced neuropathy. <i>Neuropharmacology</i> , 2020, 166, 107935.	4.1	13
23	Preclinical assessment of tramadol abuse potential: Effects of acute and repeated tramadol on intracranial self-stimulation in rats. <i>Journal of Psychopharmacology</i> , 2020, 34, 1316-1325.	4.0	2
24	Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder. <i>Neuropsychopharmacology</i> , 2020, 45, 1967-1973.	5.4	19
25	Effects of repeated treatment with monoamine-transporter-inhibitor antidepressants on pain-related depression of intracranial self-stimulation in rats. <i>Psychopharmacology</i> , 2020, 237, 2201-2212.	3.1	11
26	In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia. <i>Biological Psychiatry</i> , 2020, 88, 935-944.	1.3	30
27	Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107848.	3.2	29
28	Confronting the opioid crisis with basic research in neuropharmacology. <i>Neuropharmacology</i> , 2020, 166, 107972.	4.1	5
29	Investigation of the Optical Isomers of Methcathinone, and Two Achiral Analogs, at Monoamine Transporters and in Intracranial Self-Stimulation Studies in Rats. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1762-1769.	3.5	8
30	Evaluation of a Dual Fentanyl/Heroin Vaccine on the Antinociceptive and Reinforcing Effects of a Fentanyl/Heroin Mixture in Male and Female Rats. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1300-1310.	3.5	23
31	Resistance of Food-Maintained Operant Responding to Mechanical Punishment in Rats: Further Evidence for Weak Affective/Motivational Pain in Rat Models of Inflammatory and Neuropathic Pain. <i>Frontiers in Pharmacology</i> , 2020, 11, 615782.	3.5	6
32	Pharmacological validation of a translational model of cocaine use disorder: Effects of d-amphetamine maintenance on choice between intravenous cocaine and a nondrug alternative in humans and rhesus monkeys.. <i>Experimental and Clinical Psychopharmacology</i> , 2020, 28, 169-180.	1.8	29
33	Experimental design and analysis for consideration of sex as a biological variable. <i>Neuropsychopharmacology</i> , 2019, 44, 2159-2162.	5.4	33
34	Interactions between pain states and opioid reward assessed with intracranial self-stimulation in rats. <i>Neuropharmacology</i> , 2019, 160, 107689.	4.1	8
35	Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107501.	3.2	20
36	Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats. <i>Neuropharmacology</i> , 2019, 150, 200-209.	4.1	37

#	ARTICLE	IF	CITATIONS
37	Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats. <i>Psychopharmacology</i> , 2019, 236, 1057-1066.	3.1	16
38	Core Outcome Measures in Preclinical Assessment of Candidate Analgesics. <i>Pharmacological Reviews</i> , 2019, 71, 225-266.	16.0	67
39	Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats. <i>Neuropharmacology</i> , 2019, 151, 180-188.	4.1	12
40	Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats. <i>Neuropsychopharmacology</i> , 2019, 44, 2022-2029.	5.4	67
41	Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications. <i>Neuropsychopharmacology</i> , 2019, 44, 1011-1012.	5.4	15
42	Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys. <i>Behavioural Pharmacology</i> , 2019, 30, 358-362.	1.7	9
43	Determinants of opioid abuse potential: Insights using intracranial self-stimulation. <i>Peptides</i> , 2019, 112, 23-31.	2.4	22
44	Effects of the $\alpha 2/\alpha 3$ -subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam. <i>Behavioural Pharmacology</i> , 2019, 30, 452-461.	1.7	16
45	Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.. <i>Experimental and Clinical Psychopharmacology</i> , 2019, 27, 215-226.	1.8	32
46	Repeated Morphine Produces Sensitization to Reward and Tolerance to Antiallodynia in Male and Female Rats with Chemotherapy-Induced Neuropathy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 9-19.	2.5	21
47	Addressing the Opioid Crisis: The Importance of Choosing Translational Endpoints in Analgesic Drug Discovery. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 327-330.	8.7	24
48	Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 37-47.	2.5	24
49	Lack of paclitaxel effects on intracranial self-stimulation in male and female rats: comparison to mechanical sensitivity. <i>Behavioural Pharmacology</i> , 2018, 29, 290-298.	1.7	20
50	Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats. <i>Neuropsychopharmacology</i> , 2018, 43, 1753-1762.	5.4	15
51	Effects of <i>N</i> -Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related Behavior. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1829-1839.	3.5	10
52	Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 164, 32-39.	2.9	26
53	Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats. <i>Psychopharmacology</i> , 2018, 235, 203-213.	3.1	38
54	Abuse Potential of Biased Mu Opioid Receptor Agonists. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 916-919.	8.7	36

#	ARTICLE	IF	CITATIONS
55	Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 222-233.	2.5	7
56	Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats.. <i>Experimental and Clinical Psychopharmacology</i> , 2018, 26, 195-204.	1.8	7
57	Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys. <i>Addiction Biology</i> , 2017, 22, 1169-1178.	2.6	29
58	Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceclidine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. <i>Journal of Psychopharmacology</i> , 2017, 31, 730-739.	4.0	135
59	Role of d -amphetamine and d -methamphetamine as active metabolites of benzphetamine: Evidence from drug discrimination and pharmacokinetic studies in male rhesus monkeys. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 156, 30-38.	2.9	2
60	Relief of Pain-Depressed Behavior in Rats by Activation of D1-Like Dopamine Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 14-23.	2.5	13
61	Oral modafinil facilitates intracranial self-stimulation in rats: comparison with methylphenidate. <i>Behavioural Pharmacology</i> , 2017, 28, 318-322.	1.7	13
62	Effects of Acute and Chronic Treatments with Dopamine D ₂ and D ₃ Receptor Ligands on Cocaine versus Food Choice in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 161-176.	2.5	22
63	N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability. <i>Neuropsychopharmacology</i> , 2017, 42, 1950-1961.	5.4	26
64	Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. <i>Psychopharmacology</i> , 2017, 234, 2597-2605.	3.1	43
65	Apparent CB ₁ Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 210-218.	2.5	20
66	Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats. <i>Psychopharmacology</i> , 2017, 234, 2091-2101.	3.1	12
67	Insights from Preclinical Choice Models on Treating Drug Addiction. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 181-194.	8.7	103
68	Maintenance on naltrexone + amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2017, 181, 85-93.	3.2	8
69	Utility of Nonhuman Primates in Substance Use Disorders Research. <i>ILAR Journal</i> , 2017, 58, 202-215.	1.8	26
70	Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 152, 52-60.	2.9	13
71	Repeated 7-Day Treatment with the 5-HT _{2C} Agonist Lorcaserin or the 5-HT _{2A} Antagonist Pimavanserin Alone or in Combination Fails to Reduce Cocaine vs Food Choice in Male Rhesus Monkeys. <i>Neuropsychopharmacology</i> , 2017, 42, 1082-1092.	5.4	36
72	Effects of the kappa opioid receptor antagonist nor-BNI on cocaine versus food choice and extended-access cocaine intake in rhesus monkeys. <i>Addiction Biology</i> , 2016, 21, 360-373.	2.6	25

#	ARTICLE	IF	CITATIONS
73	Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and Δ^9 -tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats. Behavioural Pharmacology, 2016, 27, 364-376.	1.7	26
74	Cocaine-like discriminative stimulus effects of phendimetrazine and phenmetrazine in rats. Behavioural Pharmacology, 2016, 27, 192-195.	1.7	3
75	Opposing effects of dopamine D1- and D2-like agonists on intracranial self-stimulation in male rats.. Experimental and Clinical Psychopharmacology, 2016, 24, 193-205.	1.8	17
76	Preclinical Abuse Potential Assessment of Flibanserin: Effects on Intracranial Self-Stimulation in Female and Male Rats. Journal of Sexual Medicine, 2016, 13, 338-349.	0.6	9
77	Effects of 21-day d -amphetamine and risperidone treatment on cocaine vs food choice and extended-access cocaine intake in male rhesus monkeys. Drug and Alcohol Dependence, 2016, 168, 36-44.	3.2	14
78	Pharmacokineticâ€“Pharmacodynamic (PKPD) Analysis with Drug Discrimination. Current Topics in Behavioral Neurosciences, 2016, 39, 245-259.	1.7	22
79	Decoding the Structure of Abuse Potential for New Psychoactive Substances: Structureâ€“Activity Relationships for Abuse-Related Effects of 4-Substituted Methcathinone Analogs. Current Topics in Behavioral Neurosciences, 2016, 32, 119-131.	1.7	35
80	Development of a translational model to screen medications for cocaine use disorder I: Choice between cocaine and food in rhesus monkeys. Drug and Alcohol Dependence, 2016, 165, 103-110.	3.2	23
81	Stratification of Cannabinoid 1 Receptor (CB ₁) Agonist Efficacy: Manipulation of CB ₁ Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 329-339.	2.5	32
82	Development of a translational model to screen medications for cocaine use disorder II: Choice between intravenous cocaine and money in humans. Drug and Alcohol Dependence, 2016, 165, 111-119.	3.2	34
83	Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters. Scientific Reports, 2016, 6, 31385.	3.3	8
84	Effects of the noncompetitive α -methyl- α -aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats. European Journal of Pain, 2016, 20, 1229-1240.	2.8	9
85	Expression and pharmacological modulation of visceral pain-induced conditioned place aversion in mice. Neuropharmacology, 2016, 102, 236-243.	4.1	36
86	Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats. European Neuropsychopharmacology, 2016, 26, 288-297.	0.7	20
87	Comparison of effects produced by nicotine and the Δ^2 -selective agonist 5-l-A-85380 on intracranial self-stimulation in rats.. Experimental and Clinical Psychopharmacology, 2016, 24, 65-75.	1.8	14
88	Steric parameters, molecular modeling and hydrophobic interaction analysis of the pharmacology of para-substituted methcathinone analogues. British Journal of Pharmacology, 2015, 172, 2210-2218.	5.4	39
89	Effects of caffeine and its metabolite paraxanthine on intracranial self-stimulation in male rats.. Experimental and Clinical Psychopharmacology, 2015, 23, 71-80.	1.8	8
90	Effects of continuous nicotine treatment and subsequent termination on cocaine versus food choice in male rhesus monkeys.. Experimental and Clinical Psychopharmacology, 2015, 23, 395-404.	1.8	3

#	ARTICLE	IF	CITATIONS
91	Effects of repeated morphine on intracranial self-stimulation in male rats in the absence or presence of a noxious pain stimulus.. Experimental and Clinical Psychopharmacology, 2015, 23, 405-414.	1.8	31
92	Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure. International Journal of Neuropsychopharmacology, 2015, 18, ..	2.1	32
93	Abuse-Related Neurochemical Effects of Para-Substituted Methcathinone Analogs in Rats: Microdialysis Studies of Nucleus Accumbens Dopamine and Serotonin. Journal of Pharmacology and Experimental Therapeutics, 2015, 356, 182-190.	2.5	46
94	Effects of μ -Opioid Receptor Agonists in Assays of Acute Pain-Stimulated and Pain-Depressed Behavior in Male Rats: Role of μ -Agonist Efficacy and Noxious Stimulus Intensity. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 208-217.	2.5	32
95	Differential tolerance to morphine antinociception in assays of pain-stimulated vs. pain-depressed behavior in rats. European Journal of Pharmacology, 2015, 748, 76-82.	3.5	14
96	Stereoselective Actions of Methylenedioxypyrovalerone (MDPV) To Inhibit Dopamine and Norepinephrine Transporters and Facilitate Intracranial Self-Stimulation in Rats. ACS Chemical Neuroscience, 2015, 6, 771-777.	3.5	68
97	Effects of the novel, selective and low-efficacy μ opioid receptor ligand NAQ on intracranial self-stimulation in rats. Psychopharmacology, 2015, 232, 815-824.	3.1	18
98	Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice. Drug and Alcohol Dependence, 2015, 150, 31-37.	3.2	17
99	Agonist Medications for the Treatment of Cocaine Use Disorder. Neuropsychopharmacology, 2015, 40, 1815-1825.	5.4	62
100	Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. Pain, 2015, 156, 175-184.	4.2	30
101	Use of Preclinical Drug Vs. Food Choice Procedures to Evaluate Candidate Medications for Cocaine Addiction. Current Treatment Options in Psychiatry, 2015, 2, 136-150.	1.9	42
102	Role of 5-HT _{2C} receptors in effects of monoamine releasers on intracranial self-stimulation in rats. Psychopharmacology, 2015, 232, 3249-3258.	3.1	9
103	Effects of Nicotinic Acetylcholine Receptor Agonists in Assays of Acute Pain-Stimulated and Pain-Depressed Behaviors in Rats. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 343-352.	2.5	17
104	A generalized matching law analysis of cocaine vs. food choice in rhesus monkeys: Effects of candidate μ -agonist-based™ medications on sensitivity to reinforcement. Drug and Alcohol Dependence, 2015, 146, 52-60.	3.2	13
105	Quantitative structure–activity relationship analysis of the pharmacology of μ -substituted methcathinone analogues. British Journal of Pharmacology, 2015, 172, 2433-2444.	5.4	58
106	μ -Tetrahydrocannabinol and Endocannabinoid Degradative Enzyme Inhibitors Attenuate Intracranial Self-Stimulation in Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 195-207.	2.5	32
107	Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. British Journal of Pharmacology, 2015, 172, 883-894.	5.4	67
108	Effects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice. Pain, 2015, 156, 1153-1160.	4.2	70

#	ARTICLE	IF	CITATIONS
109	Sustained Pain-Related Depression of Behavior: Effects of Intraplantar Formalin and Complete Freund's Adjuvant on Intracranial Self-Stimulation (ICSS) and Endogenous kappa Opioid Biomarkers in Rats. <i>Molecular Pain</i> , 2014, 10, 1744-8069-10-62.	2.1	54
110	Effects of the neuropeptide S receptor antagonist RTI-118 on abuse-related facilitation of intracranial self-stimulation produced by cocaine and methylenedioxypyrovalerone (MDPV) in rats. <i>European Journal of Pharmacology</i> , 2014, 743, 98-105.	3.5	18
111	Monoamine Transporter Inhibitors and Substrates as Treatments for Stimulant Abuse. <i>Advances in Pharmacology</i> , 2014, 69, 129-176.	2.0	50
112	Pain-Related Depression of the Mesolimbic Dopamine System in Rats: Expression, Blockade by Analgesics, and Role of Endogenous μ -opioids. <i>Neuropsychopharmacology</i> , 2014, 39, 614-624.	5.4	78
113	Abuse-related and abuse-limiting effects of methcathinone and the synthetic α -bath salts α -cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. <i>Psychopharmacology</i> , 2014, 231, 199-207.	3.1	115
114	The effect of chronic amphetamine treatment on cocaine-induced facilitation of intracranial self-stimulation in rats. <i>Psychopharmacology</i> , 2014, 231, 2461-2470.	3.1	26
115	Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats. <i>Psychopharmacology</i> , 2014, 231, 2705-2716.	3.1	25
116	Intracranial Self-Stimulation to Evaluate Abuse Potential of Drugs. <i>Pharmacological Reviews</i> , 2014, 66, 869-917.	16.0	185
117	Rat Nucleus Accumbens Core Astrocytes Modulate Reward and the Motivation to Self-Administer Ethanol after Abstinence. <i>Neuropsychopharmacology</i> , 2014, 39, 2835-2845.	5.4	115
118	Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.. <i>Experimental and Clinical Psychopharmacology</i> , 2014, 22, 274-284.	1.8	16
119	Comparison of Antidepressant-Like and Abuse-Related Effects of Phencyclidine in Rats. <i>Drug Development Research</i> , 2014, 75, 479-488.	2.9	11
120	Role of phenmetrazine as an active metabolite of phendimetrazine: Evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2013, 130, 158-166.	3.2	33
121	Effects of 14-day treatment with the schedule III anorectic phendimetrazine on choice between cocaine and food in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2013, 131, 204-213.	3.2	38
122	Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. <i>British Journal of Pharmacology</i> , 2013, 168, 850-862.	5.4	102
123	Effects of Monoamine Reuptake Inhibitors in Assays of Acute Pain-Stimulated and Pain-Depressed Behavior in Rats. <i>Journal of Pain</i> , 2013, 14, 246-259.	1.4	63
124	Mu, Delta and Kappa Opioid Agonist Effects In Novel Assays of Pain-Depressed Behavior. <i>ACS Symposium Series</i> , 2013, , 163-176.	0.5	2
125	Interaction Between Behavioral and Pharmacological Treatment Strategies to Decrease Cocaine Choice in Rhesus Monkeys. <i>Neuropsychopharmacology</i> , 2013, 38, 395-404.	5.4	26
126	Effects of Phendimetrazine Treatment on Cocaine vs Food Choice and Extended-Access Cocaine Consumption in Rhesus Monkeys. <i>Neuropsychopharmacology</i> , 2013, 38, 2698-2707.	5.4	37

#	ARTICLE	IF	CITATIONS
127	Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats. Behavioural Pharmacology, 2013, 24, 448-458.	1.7	13
128	Abuse-related effects of μ -opioid analgesics in an assay of intracranial self-stimulation in rats. Behavioural Pharmacology, 2013, 24, 459-470.	1.7	24
129	Medications Development for Opioid Abuse. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a012104-a012104.	6.2	30
130	COCAINE VERSUS FOOD CHOICE PROCEDURE IN RATS: ENVIRONMENTAL MANIPULATIONS AND EFFECTS OF AMPHETAMINE. Journal of the Experimental Analysis of Behavior, 2013, 99, 211-233.	1.1	88
131	Expression and treatment of pain-related behavioral depression. Lab Animal, 2013, 42, 292-300.	0.4	49
132	Effects of chronic amphetamine treatment on cocaine-induced facilitation of intracranial self-stimulation in rats. FASEB Journal, 2013, 27, 1098.4.	0.5	0
133	Stereoselective effects of methcathinone on intracranial self-stimulation in rats. FASEB Journal, 2013, 27, 1098.2.	0.5	0
134	Antinociceptive effects of ± 7 nicotinic acetylcholine receptor positive allosteric modulators type I and II in models of acute and chronic pain in mice. FASEB Journal, 2013, 27, 886.14.	0.5	1
135	Effects of methadone, fentanyl and nalbuphine on intracranial self-stimulation in rats: modulation by morphine exposure. FASEB Journal, 2013, 27, 886.1.	0.5	0
136	Pain-related depression of the mesolimbic dopamine system in rats. FASEB Journal, 2013, 27, 886.10.	0.5	0
137	Role of μ -opioid receptor reserve and μ -agonist efficacy as determinants of the effects of μ -agonists on intracranial self-stimulation in rats. Behavioural Pharmacology, 2012, 23, 678-692.	1.7	29
138	Dissociable Effects of the Cannabinoid Receptor Agonists Δ^9 -Tetrahydrocannabinol and CP55940 on Pain-Stimulated Versus Pain-Depressed Behavior in Rats. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 389-400.	2.5	67
139	Effects of Peripherally Restricted μ Opioid Receptor Agonists on Pain-Related Stimulation and Depression of Behavior in Rats. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 501-509.	2.5	54
140	Preclinical Determinants of Drug Choice under Concurrent Schedules of Drug Self-Administration. Advances in Pharmacological Sciences, 2012, 2012, 1-17.	3.7	79
141	MDAN-21: A Bivalent Opioid Ligand Containing μ -Agonist and Delta-Antagonist Pharmacophores and Its Effects in Rhesus Monkeys. International Journal of Medicinal Chemistry, 2012, 2012, 1-6.	2.2	22
142	Interaction between Mu and Delta Opioid Receptor Agonists in an Assay of Capsaicin-Induced Thermal Allodynia in Rhesus Monkeys. Pain Research and Treatment, 2012, 2012, 1-8.	1.7	9
143	Effects of the Delta Opioid Receptor Agonist SNC80 on Pain-Related Depression of Intracranial Self-Stimulation (ICSS) in Rats. Journal of Pain, 2012, 13, 317-327.	1.4	27
144	Effects of monoamine releasers with varying selectivity for releasing dopamine/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys. Behavioural Pharmacology, 2011, 22, 824-836.	1.7	41

#	ARTICLE	IF	CITATIONS
145	Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology, 2010, 210, 149-159.	3.1	61
146	Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics. Pharmacology Biochemistry and Behavior, 2010, 97, 205-212.	2.9	19
147	Antinociceptive Interactions between Mu-Opioid Receptor Agonists and the Serotonin Uptake Inhibitor Clomipramine in Rhesus Monkeys: Role of Mu Agonist Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 497-505.	2.5	29
148	Effects of Extended Cocaine Access and Cocaine Withdrawal on Choice Between Cocaine and Food in Rhesus Monkeys. Neuropsychopharmacology, 2010, 35, 493-504.	5.4	28
149	Modulation of delta opioid agonist-induced antinociception by repeated morphine pretreatment in rhesus monkeys. Life Sciences, 2010, 86, 385-392.	4.3	5
150	Rationale and Methods for Assessment of Pain-Depressed Behavior in Preclinical Assays of Pain and Analgesia. Methods in Molecular Biology, 2010, 617, 79-91.	0.9	45
151	Pain-related depression of intracranial self-stimulation in rats: effects of the kappa opioid agonist U69,593 and the kappa opioid antagonist norbinaltorphimine. FASEB Journal, 2010, 24, 765.16.	0.5	0
152	Selective Suppression of Cocaine- versus Food-Maintained Responding by Monoamine Releasers in Rhesus Monkeys: Benzylpiperazine, (+)Phenmetrazine, and 4-Benzylpiperidine. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 272-281.	2.5	34
153	Mechanisms of Withdrawal-Associated Increases in Heroin Self-Administration: Pharmacologic Modulation of Heroin vs Food Choice in Heroin-Dependent Rhesus Monkeys. Neuropsychopharmacology, 2009, 34, 899-911.	5.4	60
154	Effects of the monoamine uptake inhibitors RTI-112 and RTI-113 on cocaine- and food-maintained responding in rhesus monkeys. Pharmacology Biochemistry and Behavior, 2009, 91, 333-338.	2.9	12
155	Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. Pharmacology Biochemistry and Behavior, 2009, 94, 278-284.	2.9	18
156	Role of delta opioid efficacy as a determinant of mu/delta opioid interactions in rhesus monkeys. European Journal of Pharmacology, 2009, 602, 92-100.	3.5	31
157	The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. European Journal of Pharmacology, 2009, 604, 58-65.	3.5	50
158	Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: Further studies on pain-depressed behavior. Pain, 2009, 144, 170-177.	4.2	80
159	Selective but Slight Enhancement of Delta Agonist-Induced Antinociception by Repeated Morphine in Rhesus Monkeys. FASEB Journal, 2009, 23, 742.7.	0.5	0
160	Effects of extended access and withdrawal on the reinforcing strength of cocaine using a cocaine vs. food concurrent-choice procedure in rhesus monkeys. FASEB Journal, 2009, 23, 588.10.	0.5	0
161	Behavioral Pharmacology of the δ Opioid Glycopeptide MMP2200 in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 939-948.	2.5	28
162	Mu/kappa opioid interactions in rhesus monkeys: Implications for analgesia and abuse liability.. Experimental and Clinical Psychopharmacology, 2008, 16, 386-399.	1.8	59

#	ARTICLE	IF	CITATIONS
163	Role of delta receptor efficacy as a determinant of delta/mu opioid interactions in rhesus monkeys. <i>FASEB Journal</i> , 2008, 22, 712.1.	0.5	0
164	Explaining the Escalation of Drug Use in Substance Dependence: Models and Appropriate Animal Laboratory Tests. <i>Pharmacology</i> , 2007, 80, 65-119.	2.2	127
165	Monoamine Releasers with Varying Selectivity for Dopamine/Norepinephrine versus Serotonin Release as Candidate "Agonist" Medications for Cocaine Dependence: Studies in Assays of Cocaine Discrimination and Cocaine Self-Administration in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 627-636.	2.5	70
166	Preclinical Assessment of Candidate Analgesic Drugs: Recent Advances and Future Challenges. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 507-514.	2.5	213
167	Targeting Pain-Suppressed Behaviors in Preclinical Assays of Pain and Analgesia: Effects of Morphine on Acetic Acid-Suppressed Feeding in C57BL/6J Mice. <i>Journal of Pain</i> , 2006, 7, 408-416.	1.4	92
168	Choice between Heroin and Food in Nondependent and Heroin-Dependent Rhesus Monkeys: Effects of Naloxone, Buprenorphine, and Methadone. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 711-723.	2.5	114
169	Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists. <i>Biochemical Pharmacology</i> , 2006, 71, 1663-1670.	4.4	26
170	Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 85, 744-751.	2.9	18
171	Interactions between the reinforcing effects of cocaine and heroin in a drug-vs-food choice procedure in rhesus monkeys: a dose-addition analysis. <i>Psychopharmacology</i> , 2005, 180, 115-124.	3.1	38
172	Effects of punishment on choice between cocaine and food in rhesus monkeys. <i>Psychopharmacology</i> , 2005, 181, 244-252.	3.1	60
173	Effect of Gonadectomy and Gonadal Hormone Replacement on Cocaine Self-Administration in Female and Male Rats. <i>Neuropsychopharmacology</i> , 2004, 29, 929-942.	5.4	95
174	Ovarian Steroid Hormone Modulation of the Acute Effects of Cocaine on Luteinizing Hormone and Prolactin Levels in Ovariectomized Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 156-167.	2.5	6
175	The utility of "tolerance" as a concept in the study of drug self-administration. <i>Psychopharmacology</i> , 2004, 171, 362-363.	3.1	6
176	Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys. <i>Psychopharmacology</i> , 2004, 176, 204-213.	3.1	73
177	Effects of chronic methadone treatment on cocaine- and food-maintained responding under second-order, progressive-ratio and concurrent-choice schedules in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2004, 74, 297-309.	3.2	36
178	Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. <i>Addictive Behaviors</i> , 2004, 29, 1439-1464.	3.0	244
179	Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. <i>Psychopharmacology</i> , 2003, 167, 324-332.	3.1	94
180	Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and "funaltrexamine. <i>Drug and Alcohol Dependence</i> , 2003, 70, 17-27.	3.2	15

#	ARTICLE	IF	CITATIONS
181	Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , 2003, 70, 39-52.	3.2	174
182	Opioid Interactions in Rhesus Monkeys: Effects of $\hat{\imath} + \hat{\imath}^{1/4}$ and $\hat{\imath} + \hat{\imath}^{\circ}$ Agonists on Schedule-Controlled Responding and Thermal Nociception. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 1054-1064.	2.5	58
183	Rapid Assessment of Choice between Cocaine and Food in Rhesus Monkeys: Effects of Environmental Manipulations and Treatment with d-Amphetamine and Flupenthixol. <i>Neuropsychopharmacology</i> , 2003, 28, 919-931.	5.4	186
184	Effects of $\hat{\imath}^{1/4}$ -Opioid Agonists on Cocaine- and Food-Maintained Responding and Cocaine Discrimination in Rhesus Monkeys: Role of $\hat{\imath}^{1/4}$ -Agonist Efficacy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 1111-1121.	2.5	39
185	Antagonism of the Antinociceptive and Discriminative Stimulus Effects of Heroin and Morphine by 3-Methoxynaltrexone and Naltrexone in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 264-273.	2.5	34
186	Delta opioid antagonist effects of buprenorphine in rhesus monkeys. <i>Behavioural Pharmacology</i> , 2002, 13, 557-570.	1.7	58
187	Sex differences in opioid antinociception in rhesus monkeys: Antagonism of fentanyl and U50,488 by quadazocine. <i>Journal of Pain</i> , 2002, 3, 218-226.	1.4	29
188	Kappa opioid antagonist effects of the novel kappa antagonist 5?-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. <i>Psychopharmacology</i> , 2002, 163, 412-419.	3.1	60
189	Interactions between Kappa Opioid Agonists and Cocaine: Preclinical Studies. <i>Annals of the New York Academy of Sciences</i> , 2000, 909, 104-132.	3.8	110
190	Antinociceptive Effects of Cocaine in Rhesus Monkeys. <i>Pharmacology Biochemistry and Behavior</i> , 1999, 62, 291-297.	2.9	10
191	Opioid antinociception in ovariectomized monkeys: comparison with antinociception in males and effects of estradiol replacement. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999, 290, 1132-40.	2.5	77
192	Effects of Mu Opioid Agonists Alone and in Combination with Cocaine and D-Amphetamine in Rhesus Monkeys Trained to Discriminate Cocaine. <i>Neuropsychopharmacology</i> , 1998, 18, 325-338.	5.4	35
193	Antinociceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu opioid agonists in rhesus monkeys. <i>Psychopharmacology</i> , 1998, 135, 99-106.	3.1	46
194	Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1998, 286, 362-75.	2.5	103
195	Effects of kappa opioids on cocaine self-administration by rhesus monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1997, 282, 44-55.	2.5	115
196	Preclinical Evaluation of Pharmacotherapies for Treatment of Cocaine and Opioid Abuse Using Drug Self-Administration Procedures. <i>Neuropsychopharmacology</i> , 1996, 14, 375-424.	5.4	346
197	Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1996, 278, 879-90.	2.5	36
198	Relationship between the discriminative stimulus effects and plasma concentrations of intramuscular cocaine in rhesus monkeys. <i>Psychopharmacology</i> , 1995, 121, 331-338.	3.1	29

#	ARTICLE	IF	CITATIONS
199	Effects of morphine and ketorolac on thermal allodynia induced by prostaglandin E2 and bradykinin in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 1995, 274, 805-14.	2.5	12
200	Role of delta opioid receptors in the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 1995, 273, 1245-56.	2.5	35
201	Antinociceptive effects of cocaine/opioid combinations in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 1995, 275, 1346-54.	2.5	19
202	Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 1994, 270, 1025-34.	2.5	63
203	Drugs and stimulus control: generalization, discrimination and threshold procedures. Handbook of Behavioral Neuroscience, 1993, 10, 117-145.	0.0	2
204	Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine. Journal of Pharmacology and Experimental Therapeutics, 1993, 267, 896-903.	2.5	63
205	Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 1993, 267, 1269-76.	2.5	67
206	Prostaglandin E2-induced thermal hyperalgesia and its reversal by morphine in the warm-water tail-withdrawal procedure in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 1993, 266, 1355-63.	2.5	22
207	Intermediate efficacy mu opioids: examination of their morphine-like stimulus effects and response rate-decreasing effects in morphine-tolerant rats. Journal of Pharmacology and Experimental Therapeutics, 1992, 263, 668-81.	2.5	17
208	Public Information Service. Science, 1962, 135, 545-547.	12.6	0